ALS treatment now available in liquid formulation

Teglutik is a new liquid formulation of riluzole that can be prescribed to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).

Riluzole is the only licensed drug for patients with ALS, 80% of whom are unable to swallow as a result of dysphagia. It was previously only available in tablet form.

"The availability of a new liquid form of riluzole will be of great benefit to everyone involved in the care of patients with ALS," said Dr Katie Sidle, Co-Director MNDA MND Care and Research Centre at the National Hospital for Neurology and Neurosurgery, London. "Many will suffer the distress of having to discontinue treatment due to their inability to swallow the current formulation of riluzole, the only treatment option available to treat ALS."

The new liquid formulation is bioequivalent to riluzole tablets.

Further information
View Teglutik drug record
Summary of Product Characteristics
Manufacturer: Martindale Pharmaceuticals

Riluzole is thought to act by inhibiting glutamate processes that have a role in cell death of patients with ALS.

NICE recommends that treatment of ALS be initiated by a specialist but supervision can be managed by GPs under shared care agreements.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases